Relevant bibliographies by topics / Cardiovascular Disease Mortality

Academic literature on the topic 'Cardiovascular Disease Mortality'

Author: Grafiati
Published: 10 December 2022
Last updated: 30 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cardiovascular Disease Mortality.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cardiovascular Disease Mortality"

1

Ross, Stephanie Maxine. "Cardiovascular Disease Mortality." Holistic Nursing Practice 29, no. 1 (2015): 53–57. http://dx.doi.org/10.1097/hnp.0000000000000066.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Liu, Jiangmei, Jinlei Qi, Peng Yin, Yunning Liu, Jinling You, Lin Lin, Maigeng Zhou, and Lijun Wang. "Cardiovascular Disease Mortality — China, 2019." China CDC Weekly 3, no. 15 (2021): 323–26. http://dx.doi.org/10.46234/ccdcw2021.087.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Humblet, Olivier, Linda Birnbaum, Eric Rimm, Murray A. Mittleman, and Russ Hauser. "Dioxins and Cardiovascular Disease Mortality." Environmental Health Perspectives 116, no. 11 (November 2008): 1443–48. http://dx.doi.org/10.1289/ehp.11579.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

The Lancet. "Salt and cardiovascular disease mortality." Lancet 377, no. 9778 (May 2011): 1626. http://dx.doi.org/10.1016/s0140-6736(11)60657-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hagger-Johnson, Gareth, Beverly Roberts, David Boniface, Séverine Sabia, G. David Batty, Alexis Elbaz, Archana Singh-Manoux, and Ian J. Deary. "Neuroticism and Cardiovascular Disease Mortality." Psychosomatic Medicine 74, no. 6 (2012): 596–603. http://dx.doi.org/10.1097/psy.0b013e31825c85ca.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Radojčić, Suzana. "Mortality from cardiovascular disease in Serbia." Zdravstvena zastita 39, no. 6 (2010): 51–56. http://dx.doi.org/10.5937/zz1004051r.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Oman, D., and C. E. Thoresen. "Sex differences in cardiovascular disease mortality." American Journal of Public Health 89, no. 9 (September 1999): 1441. http://dx.doi.org/10.2105/ajph.89.9.1441.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

D??Addato, S., A. Dormi, C. Borghi, A. Miconi, and A. Gaddi. "Physical Activity and Cardiovascular Disease Mortality." High Blood Pressure & Cardiovascular Prevention 12, no. 3 (2005): 159. http://dx.doi.org/10.2165/00151642-200512030-00041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Slattery, M. L., and D. R. Jacobs. "Physical Fitness and Cardiovascular Disease Mortality." Journal of Cardiopulmonary Rehabilitation 8, no. 6 (June 1988): 241. http://dx.doi.org/10.1097/00008483-198806000-00013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pilz, Stefan, Andreas Tomaschitz, Winfried März, Christiane Drechsler, Eberhard Ritz, Armin Zittermann, Etienne Cavalier, et al. "Vitamin D, cardiovascular disease and mortality." Clinical Endocrinology 75, no. 5 (October 4, 2011): 575–84. http://dx.doi.org/10.1111/j.1365-2265.2011.04147.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cardiovascular Disease Mortality"

1

Goh, Gek Huang Louise. "Risk score for predicting cardiovascular disease mortality in Australian women." Thesis, Curtin University, 2014. http://hdl.handle.net/20.500.11937/223.

Full text
Abstract:
Louise evaluated the utility of risk score models for predicting cardiovascular mortality in Australian women. She found that most risk models do not diagnose “at risk” women well. Currently published predicted risk levels used for screening and recommending treatment are ineffective. Lower treatment thresholds are recommended. Central obesity and ethnicity have been identified for inclusion in future models. Her study has important implications for improving the accuracy of identifying “at risk” women for preventive treatment.
APA, Harvard, Vancouver, ISO, and other styles
2

Deniz, Nathalie. "Ethnicity and Cardiovascular Disease in theMiddle East." Thesis, Högskolan i Gävle, Avdelningen för arbets- och folkhälsovetenskap, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:hig:diva-14691.

Full text
Abstract:
The purpose of this study was to compare between ethnicities if there is a difference in survival and treatment when it comes to cardiovascular diseases in the Middle East. To find out if there is a difference 28 articles was selected for inclusion, both qualitative and quantitative studies. Searches were made in the databases Medline, PubMed, Google and Google Scholar.The results showed that it is possible that there are differences in mortality and morbidity between ethnicities affected by cardiovascular disease. These may be due to differences in abdominal obesity, insulin resistance in diabetes and other risks such as C-reactive protein in the blood plasma which is normally excreted in inflammation in the body and also adiponectin, which is a hormone found in fat tissue whose secretion is diminished in people who have diabetes. But studies saying that a difference does exist are too few and the need for more and larger studies is needed. It may also be that not all ethnicities are as benefited from current treatments available against cardiovascular diseases for example beta-blockers. The conclusion of this study is that more research in this area is needed as well as more comprehensive studies regarding public health in the Middle East.
Syftet med denna studie var att jämföra mellan etniska grupper om det finns en skillnad i överlevnad och behandling när det gäller hjärt-och kärlsjukdomar i Mellanöstern. För att ta reda på det har 28 artiklar valts ut efter inklusionskriterierna, både kvalitativa och kvantitativa studier. Sökningar gjordes i databaserna Medline, Pubmed, Google and Google Scholar.Resultatet visade på att det sannolikt finns skillnader i dödlighet samt sjuklighet mellan etniciteter som drabbats av hjärt- och kärlsjukdomar. Dessa kan bero på skillnader i abdominal fetma, insulin resistens vid diabetes och andra risker så som C-reaktivt protein som finns i blodplasman och i vanliga fall utsöndras vid inflammationer i kroppen och adiponectin som är ett hormon som finns i fettvävnaden vars utsöndring är sämre hos personer som har diabetes. Dock är studierna som visar på skillnader alldeles för få, det behövs fler och större undersökningar inom detta område. Denna litteratur översikt visar också att det även kan vara så att inte alla etniciteter gynnas av dagens behandlingar som finns mot hjärt- och kärlsjukdomar som t ex Betablockerare. Slutsatsen i denna studie är att mer forskning inom ämnet behövs samt fler övergripande studier gällande folkhälsan i Mellanöstern.
APA, Harvard, Vancouver, ISO, and other styles
3

Wang, Xin. "Physical activity and cardiovascular disease mortality, morbidity and all-cause mortality in Chinese elderly people." Click to view the E-thesis via HKUTO, 2008. http://sunzi.lib.hku.hk/hkuto/record/B41508257.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Holmlund, Anders. "Oral health and cardiovascular disease." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-8708.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ajwani, Shilpi. "Periodontal disease in an aged population, and its role in cardiovascular mortality." Helsinki : University of Helsinki, 2003. http://ethesis.helsinki.fi/julkaisut/laa/hamma/vk/ajwani/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wang, Xin, and 王昕. "Physical activity and cardiovascular disease mortality, morbidity and all-cause mortality in Chinese elderly people." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2008. http://hub.hku.hk/bib/B41508257.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Molloy, Eamonn S. "Cardiovascular Outcomes and In-Hospital Mortality in Giant Cell Arteritis." Case Western Reserve University School of Graduate Studies / OhioLINK, 2008. http://rave.ohiolink.edu/etdc/view?acc_num=case1212093974.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Djietror, Godwin A. Elliott Susan J. "Towards an understanding of geographic variation in cardiovascular disease mortality and morbidity in Ontario, 1986--1994 /." *McMaster only, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Guasch, Ferré Marta. "Components of the mediterranean diet on cardiovascular disease and mortality in a population at high cardiovascular risk." Doctoral thesis, Universitat Rovira i Virgili, 2014. http://hdl.handle.net/10803/284450.

Full text
Abstract:
Les malalties cardiovasculars (CV) són una de les primeres causes de morbimortalitat a tot el món. Aquestes malalties, en gran mesura, es podrien prevenir. La Dieta Mediterrània ha estat reconeguda com un dels patrons alimentaris més saludables. Fins el moment, existeix una forta evidència científica que demostra els beneficis de la dieta Mediterrània en la prevenció i el tractament de la malaltia cardiovascular. Aquesta tesi ha estat realitzada en el context de l’estudi PREDIMED, un estudi clínic paral•lel, multi cèntric i aleatoritzat que avaluava l’efecte de la dieta Mediterrània, en comparació a una dieta baixa en greix, en la prevenció primària de la malaltia cardiovascular. L’objectiu va ser determinar l’efecte dels fruits secs, l'oli d’oliva i les seves varietats, i el magnesi en el risc cardiovascular, mortalitat per causa específica i mortalitat per totes les causes en una població Mediterrània amb alt risc cardiovascular. Tots els aliments avaluats són components claus del patró de dieta Mediterrània i són consumits en altes quantitats en la nostra població. Els resultats del nostre treball demostren que consumir fruits secs amb més freqüència estava inversament relacionat amb la mortalitat cardiovascular, mortalitat per càncer i mortalitat total després de seguir als participants durant una mitja de 4.8 anys. L’oli d’oliva, concretament la varietat extra verge, s’associava a un risc reduït de malaltia cardiovascular i mortalitat cardiovascular després de 4.8 anys de mitja de seguiment. També vam observar que el magnesi dietètic s’associava inversament a la mort cardiovascular, per càncer i mortalitat total. En conclusió, els resultats d’aquesta tesi corroboren els efectes beneficiosos dels components de la dieta Mediterrània en la prevenció de malaltia cardiovascular i mort.
Las enfermedades cardiovasculares (CV) son una de las primeras causas de morbi-mortalidad en todo el mundo. Estas enfermedades, en gran medida, se podrían prevenir. La Dieta Mediterránea ha sido reconocida como uno de los patrones alimentarios más saludables. Hasta el momento, existe una fuerte evidencia científica que demuestra los beneficios de la dieta Mediterránea en la prevención y el tratamiento de la enfermedad cardiovascular. Esta tesis ha sido realizada en el contexto del estudio PREDIMED, un estudio clínico paralelo, multicéntrico y aleatorizado que evalúa el efecto de la dieta mediterránea, en comparación a una dieta baja en grasa, en la prevención primaria de la enfermedad cardiovascular. El objetivo fue determinar el efecto de los frutos secos, aceite de oliva y magnesio en el riesgo cardiovascular, mortalidad por causa específica y mortalidad por todas las causas en una población Mediterráneo con alto riesgo cardiovascular. Todos los alimentos evaluados son componentes claves del patrón de dieta Mediterránea y son consumidos en altas cantidades en nuestra población. Los resultados del presente trabajo demostraron que consumir frutos secos con más frecuencia estaba inversamente relacionado con la mortalidad cardiovascular, mortalidad por cáncer y mortalidad total tras seguir a los participantes durante una media de 4.8 años. Observamos también que el aceite de oliva, concretamente la variedad extra virgen, se asociaba a un riesgo reducido de enfermedad cardiovascular y mortalidad cardiovascular después de 4.8 años de media de seguimiento. También observamos que el magnesio dietético se asociaba inversamente a la muerte cardiovascular, por cáncer y mortalidad total. En conclusión, los resultados corroboran los efectos beneficiosos de los componentes de la dieta Mediterránea en la prevención de enfermedad cardiovascular y muerte.
Cardiovascular disease (CVD) is one of the main causes of disability and death worldwide. Importantly, in a large extent, CVD are preventable. The Mediterranean Diet (MedDiet) is recognized as one of the healthier dietary patterns. To date, strong evidence exists supporting the benefits of the MedDiet for the prevention and management of CVD. This thesis has been conducted in the framework of the PREDIMED Study, a parallel-group, multicenter randomized nutrition trial evaluating the efficacy of a MedDiet compared to a low-fat control diet on the primary prevention of CVD. We aimed to asses the associations between nuts, olive oil and its varieties, and magnesium on the risk of CVD, cause-specific and all-cause mortality on an elderly Mediterranean population at high cardiovascular risk. All of these foods are key components of the MedDiet pattern and are highly consumed in our population. The results of the present work demonstrate that the frequency of nut consumption was inversely related to cardiovascular, cancer and total mortality after 4.8 years of follow-up. We found that olive oil consumption, specifically the extra-virgin variety, was associated with reduced risk of cardiovascular disease and cardiovascular mortality after 4.8 years of follow-up. We have also observed that dietary magnesium intake was inversely associated with cardiovascular, cancer and total mortality risk after 4.8 years of follow-up. In conclusion, the findings of this thesis support the healthy benefits of the components of a MedDiet on the primary prevention of cardiovascular disease and mortality.
APA, Harvard, Vancouver, ISO, and other styles
10

Soveri, Inga. "Renal Dysfunction and Cardiovascular Disease." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-6941.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cardiovascular Disease Mortality"

1

Cardiovascular disease. New York, N.Y: Facts on File, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Waters, Anne-Marie. Mortality from cardiovascular disease in Australia. Canberra: Australian Institue of Health and Welfare, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Armitage, Jeff. Cardiovascular disease mortality and risk factors by Nebraska's local public health department regions. Lincoln, NE: Nebraska Health and Human Services System, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cardiovascular disease in racial and ethnic minorities. Totowa, N.J: Humana, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Illinois. Dept. of Public Health. Heart disease and stroke in Illinois: Now is the time for public health action : 2007-2012 state plan. Springfield, IL: Illinois Dept. of Public Health, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

D'Espaignet, E. Tursan. Trends in Australian mortality: Diseases of the circulatory system, 1950-1991. Canberra: Australian Govt. Pub. Service, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

1934-, Bruhn John G., ed. The power of clan: The influence of human relationships on heart disease. New Brunswick, N.J. U.S.A: Transaction Publishers, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Migliónico, Américo. 118 años de mortalidad por enfermedades cardiovasculares en el Uruguay, 1882 a 1999. Montevideo: Comisión Honoraria para la Salud Cardiovascular, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ronellenfitsch, Ulrich. Cardiovascular mortality among ethnic German immigrants from the former Soviet Union. Frankfurt am Main: Peter Lang, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hanke, Wojciech. Przyczyny wysokiej umieralności mężczyzn w wieku produkcyjnym w Polsce: Badania ankietowe 1987-1989. Warszawa: Szkoła Główna Handlowa, Instytut Statystyki i Demografii, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cardiovascular Disease Mortality"

1

Criqui, Michael H. "Alcohol and Cardiovascular Mortality." In Behavioral Epidemiology and Disease Prevention, 67–90. Boston, MA: Springer US, 1985. http://dx.doi.org/10.1007/978-1-4684-7929-4_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

LaRosa, John C. "Cholesterol Lowering, Low Cholesterol, and Mortality." In Cardiovascular Disease 2, 347–51. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-1959-1_44.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gordon, David J. "Cholesterol and Mortality: What Can Meta-Analysis Tell Us?" In Cardiovascular Disease 2, 333–40. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-1959-1_42.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Yeap, Bu B. "Plasma Testosterone and Dihydrotestosterone as Markers of Heart Disease and Mortality in Older Men." In Biomarkers in Cardiovascular Disease, 425–47. Dordrecht: Springer Netherlands, 2016. http://dx.doi.org/10.1007/978-94-007-7678-4_38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Yeap, Bu B. "Plasma Testosterone and Dihydrotestosterone as Markers of Heart Disease and Mortality in Older Men." In Biomarkers in Cardiovascular Disease, 1–23. Dordrecht: Springer Netherlands, 2015. http://dx.doi.org/10.1007/978-94-007-7741-5_38-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Schulman, Steven P., and Gary Gerstenblith. "Age and Mortality and Morbidity in ST-Segment Elevation Myocardial Infarction." In Cardiovascular Disease in the Elderly, 121–40. Totowa, NJ: Humana Press, 2005. http://dx.doi.org/10.1385/1-59259-941-9:121.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Thun, Michael J., Jane Henley, and Aron Rosenthal. "What Influences the Relationship Between Alcohol Consumption and Total Mortality?" In Moderate Alcohol Consumption and Cardiovascular Disease, 95–103. Dordrecht: Springer Netherlands, 2000. http://dx.doi.org/10.1007/978-94-011-4307-3_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tietze, Sara L., and Richard Lincoln. "The Pill and Mortality from Cardiovascular Disease: Another Look." In Fertility Regulation and the Public Health, 305–10. New York, NY: Springer New York, 1987. http://dx.doi.org/10.1007/978-1-4612-4702-9_32.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Dean, Charles E. "Antipsychotics and the Metabolic Syndrome, Cardiovascular Disease, and Mortality." In The Skeptical Professional’s Guide to Psychiatry, 72–94. New York, NY : Routledge, 2021.: Routledge, 2020. http://dx.doi.org/10.4324/9781003032038-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Samsioe, Göran. "Cardiovascular Disease: Reduced Mortality with Long-Term HRT Treatment." In Medical Science Symposia Series, 119–24. Dordrecht: Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-011-5560-1_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cardiovascular Disease Mortality"

1

Sekitoleko, I., N. Robertson, C. Anonubi, P. D. Jackson, R. Padalker, P. Herrera, M. Nyirenda, E. Webb, N. M. Punjabi, and T. Siddharthan. "Influence of Lung Function and Cardiovascular Disease on Mortality." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"Modernising Morbidity and Mortality: Features of Cardiovascular Diseases of the Population of the RSFSR in 1960s." In XII Ural Demographic Forum “Paradigms and models of demographic development”. Institute of Economics of the Ural Branch of the Russian Academy of Sciences, 2021. http://dx.doi.org/10.17059/udf-2021-1-1.

Full text
Abstract:
The article uses archival and published data to study the features of a type of morbidity and mortality of the Russian population observed in the 1960s. The spread of cardiovascular diseases, especially coronary heart disease and atherosclerosis, was noted in the Russian Soviet Federative Socialist Republic (RSFSR). The main reasons for the occurrence of these diseases were considered. Studies conducted in the 1960s showed a high level of disability in patients with such diseases. It was emphasized that cardiovascular diseases gave the highest mortality rates, especially in the urban population. In cities, as well as in the RSFSR as a whole, cardiovascular diseases and mortality from them were common in both men and women (middle-aged and elderly). At the same time, mortality from these diseases was also recorded in groups of young able-bodied people. It was shown that the new type of morbidity and mortality of the population caused the need to focus on health values in the country, improve environmental conditions, transform the work of medical and preventive institutions, and change the lifestyle of the population.
APA, Harvard, Vancouver, ISO, and other styles
3

Mannino, David M., Kourtney J. Davis, and Rachael L. DiSantostefano. "Chronic Respiratory Disease, Comorbid Cardiovascular Disease, And Mortality In A Representative U.S. Cohort." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mesihović-Dinarević, Senka. "UPDATE IN DIAGNOSTICS CARDIOLOGY." In International Scientific Symposium “Diagnostics in Cardiology and Grown-Up Congenital Heart Disease (GUCH)”. Academy of Sciences and Arts of Bosnia and Herzegovina, 2021. http://dx.doi.org/10.5644/pi2021.199.02.

Full text
Abstract:
Cardiovascular medicine is an area of clinical practice with a continually rapid expansion of knowledge, guidelines, best practices and new technology in adult cardiovascular medicine as well as in paediatric cardiology medicine. Cardiovascular diseases (CVD) are the leading cause of mortality in the world and cause major costs for the health sector and economy. Cardiovascular imaging indices have a significant impact on the prevention, diagnosis, and treatment of cardiac diseases. Advanced imaging technologies have dramatically improved our ability to detect and treat cardiovascular disease at an early stage. Multimodality imaging techniques - echocardiogram, cardiac computerized tomography, magnetic resonance imaging, simulation 3D models, artificial intelligence - are being used more frequently as their utility is better appreciated. Coronavirus disease 2019 (COVID-19) exerts an unprecedented global impact on public health and health care delivery. Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) causing COVID-19 has reached pandemic levels since March 2020. Patients with cardiovascular (CV) risk factors and established CVD represent a vulnerable population when suffering from COVID-19, and have an increased risk of morbidity and mortality. Severe COVID-19 infection is associated with myocardial damage and cardiac arrhythmia. Diagnostic workup during SARS infection revealed electrocardiographic changes, sub-clinical left ventricular (LV) diastolic impairment and troponin elevation. All professionals in cardiovascular medicine, as a part of lifelong learning process, have the continuous imperative in reviewing novelties, with results data from numerous researches in order to treat all patients according to best practices and evidence-based medicine, especially on this journey through corona pandemic.
APA, Harvard, Vancouver, ISO, and other styles
5

Harris, William, and Irum Zahara. "Omega-3 and cardiovascular disease." In 2022 AOCS Annual Meeting & Expo. American Oil Chemists' Society (AOCS), 2022. http://dx.doi.org/10.21748/rrxh5251.

Full text
Abstract:
Despite the fact that the “omega-3 lowers risk for CVD” story is now 50 years old, controversies remain regarding the short and long-term utility of omega-3 supplementation to reduce risk for CVD. The earlier studies (published roughly before 2007) were generally favorable, however a spate of studies published since then were not nearly as clear. The one stand-out in the latter set was REDUCE-IT, which used 4 g/d of EPA ethyl esters (instead of EPA+DHA ethyl esters). In this study, the treated subjects experienced about 25% fewer CVD events than the placebo group. This resulted in FDA approval for this drug for reducing risk for CVD in specific patient populations. The next large study to report out – STRENGTH – was expected to be positive as well (3.1 g EPA+DHA as free fatty acids), but it was stopped early for “futility” (i.e., the event rates were not different between active and placebo groups). Many hypotheses have been raised to explain these wildly different outcomes, and this has engendered considerable confusion in the field. These hypotheses will be discussed in this presentation. On the other hand, observational prospective cohort studies based on measured blood omega-3 levels (not on fish intake questionnaires) have consistently shown that higher levels are associated with lower risk for CVD (and total mortality). These two different study designs (RCTs vs observational epidemiology) ask different questions. This talk will synthesize these two apparently divergent conclusions regarding the utility of omega-3 fatty acids for reducing risk for CVD.
APA, Harvard, Vancouver, ISO, and other styles
6

Miller, David P., Tim Sampson, Janusz Kaminski, and Kourtney Davis. "Mortality Rates In COPD Patients With Cardiovascular Disease In The UK." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5946.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Imamovic, Damir, Elmir Babovic, and Nina Bijedic. "Prediction of mortality in patients with cardiovascular disease using data mining methods." In 2020 19th International Symposium INFOTEH-JAHORINA (INFOTEH). IEEE, 2020. http://dx.doi.org/10.1109/infoteh48170.2020.9066297.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bhatnagar, P., and N. Townsend. "P34 Explaining differences in cardiovascular disease mortality between local authorities in england." In Society for Social Medicine, 61st Annual Scientific Meeting, University of Manchester, 5–8 September 2017. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/jech-2017-ssmabstracts.136.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mesihović-Dinarević, Senka. "WHAT IS NEW IN CARDIOVASCULAR MEDICINE?" In Symposium with International Participation HEART AND … Akademija nauka i umjetnosti Bosne i Hercegovine, 2019. http://dx.doi.org/10.5644/pi2019.181.03.

Full text
Abstract:
The rapid pace of change continues to be a hallmark in cardiovascular medicine and many see that pace accelerating in adult cardiovascular medicine as well as in paediatric cardiology medicine. Cardiovascular medicine is an area of clinical practice with a continually rapid expansion of knowledge, guidelines, best practices and new technology. Cardiovascular diseases are the leading cause of mortality in the world and cause major costs for the health sector and economy. Primary care clinicians are challenged to optimally manage a multitude of diseases including congestive heart failure, coronary artery disease, valvular diseases, arrhythmias, lipid disorders, and hypertension. Multimodality imaging techniques are being used more frequently as their utility is better appreciated. Echocardiography has been the mainstay approach, cardiac computerized tomography and magnetic resonance imaging provide a good imaging alternative for patients with multiple complex surgeries. 3D printing has seen a rapid growth in use for planning treatments for patients with congenital heart disease. Simulation using 3D models is emerging as a fundamental resource for teaching procedural techniques and a new standard of care. Artificial intelligence holds the greatest potential for revolutionizing medicine. Innovative technologies in the world of cardiovascular health are expanding every day: wearable computing technologies, bioresorbable stents, leadless pacemaker, valve-in-valve procedure, protein patch for heart muscle growth and others. As a part of lifelong learning process for all professionals in cardiovascular medicine, the imperative is to have continuity of reviewing novelties, with results data from numerous researches in order to treat patient according to best practices and evidence-based medicine.
APA, Harvard, Vancouver, ISO, and other styles
10

Zahedmanesh, Houman, Paul Gatenholm, and Caitríona Lally. "Bacterial Cellulose: A Potential Vascular Graft and Tissue Engineering Scaffold." In ASME 2009 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2009. http://dx.doi.org/10.1115/sbc2009-206343.

Full text
Abstract:
Cardiovascular disease is the major cause of morbidity and mortality in the adult population and treatment of many of the patients struggling with such diseases requires surgical interventions involving replacement of diseased arteries. Although currently it is possible to replace large arteries with synthetic grafts made of materials such as polyester and expanded polytetrafluoroethylene (ePTFE) [1], these materials may not be used as small size grafts given their thrombogenicity and propensity for intimal hyperplasia [2]. As a result, development of suitable grafts as a substitute for small size arteries (< 6mm in diameter) such as the coronary arteries remains a daunting challenge.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cardiovascular Disease Mortality"

1

Hua, Minglei, Ling Li, and Linlin Diao. Bronchial asthma and risk of cardiovascular disease and cardiovascular mortality: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2022. http://dx.doi.org/10.37766/inplasy2022.2.0083.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zhang, Mingzhu, Wujisiguleng Bao, Luying Sun, Zhi Yao, and Xiyao Li. Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: meta-analysis of randomized clinical trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0020.

Full text
Abstract:
Review question / Objective: To assess the beneficial effect and safety of finerenone for patients with chronic kidney disease associated with type 2 diabetes. Condition being studied: Chronic kidney disease (CKD) is a major contributor to morbidity and mortality from non-communicable diseases, affecting almost 700 million people worldwide. Approximately 40% of patients with diabetes have CKD, which exposes them to a 3-fold higher risk of cardiovascular death versus those with T2D alone. Strategies to protect the kidneys of patients with CKD and T2D may reduce their risk of cardiovascular events. Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced composite kidney and cardiovascular outcome in trials involving patients with chronic kidney disease. Recently, quite a few clinical studies have been conducted to compare finerenone and placebo. Our meta-analysis aimed to investigate the efficacy and safety of finerenone in chronic kidney disease associated with T2D. 1st author* - Mingzhu Zhang and Wujisiguleng Bao contributed equally to this study.
APA, Harvard, Vancouver, ISO, and other styles
3

Zhou, Zhongwei, Hao Jin, Huixiang Ju, Mingzhong Sun, Hongmei Chen, and Li Li. Circulating trimethylamine-N-oxide and all-cause or cardiovascular mortality risk in patients with chronic kidney disease: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2021. http://dx.doi.org/10.37766/inplasy2021.10.0049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Li, Li, Jianxiu Yu, Huixiang Ju, Hao Jin, Hongmei Chen, Mingzhong Sun, and Zhongwei Zhou. Serum Amyloid A and the Risk of Cardiovascular or All-Cause Mortality in Chronic Kidney Disease: A Systematic Review and Dose-Response Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Liu, Kefeng, Zhirong Yang, Wang Miao, Bang Zheng, Shanshan Wu, Shuzhang Du, Xiaojian Zhang, Yang Zhao, Shusen Sun, and Jie Zhao. Vitamin B12 levels and risk of all-cause, cardiovascular disease and cancer mortality: a systematic review and dose-response meta-analysis of cohort studies. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0129.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Shalganov, Tchavdar, Milko Stoyanov, and Vassil Traykov. Outcomes following catheter ablation for ventricular tachycardia in adult patients with structural heart disease and implantable cardioverter-defibrillator: protocol for an updated systematic review and meta-analysis of randomized studies. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0080.

Full text
Abstract:
Review question / Objective: Does catheter ablation for scar-related monomorphic ventricular tachycardia improve outcomes (defined as any appropriate ICD therapy, appropriate ICD shocks, all-cause mortality, VT storm, cardiovascular mortality, cardiovascular hospitalizations, complications) in adult patients with ischemic or non-ischemic cardiomyopathy and implantable cardioverter-defibrillator? Condition being studied: Ventricular tachycardia in patients with structural heart disease is usually an arrhythmia using the myocardial scar as a substrate for reentry. It poses a risk of syncope and sudden cardiac death, especially in patients with reduced ejection fraction. Most antiarrhythmic drugs are of little value and their use is restricted in patients with LV systolic dysfunction. Catheter ablation is a viable option for the treatment of ventricular tachycardia. In patients with previous myocardial infarction the arrhythmogenic scar is located most frequently subendocardially and is readily accessible using endocardial approach, while in non-ischemic cardiomyopathy the scar is frequently located in the midmyocardial or subepicardial layers. This is the reason endocardial catheter ablation to be less effective in those patients and to more often necessitate epicardial approach.
APA, Harvard, Vancouver, ISO, and other styles
7

Horvit, Andrew, and Donald Molony. A Systematic Review and Meta-Analysis of Mortality and Kidney Function in Uranium – Exposed Individuals. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0122.

Full text
Abstract:
Review question / Objective: 1) In humans, how does environmental and/or occupational exposure to uranium affect the risk of mortality due to primary kidney disease compared to unexposed individuals? (2) In humans, how does environmental and/or occupational exposure to uranium affect the risk of developing kidney failure compared to unexposed individuals? Eligibility criteria: We included cohort studies that evaluate the risk of CKD/ESKD due to uranium exposure. We also included cohort studies that evaluate standardized mortality due to all-cause mortality, kidney cancer, chronic kidney disease, diabetes, and cardiovascular disease in humans with exposure to uranium. We also included cross sectional studies that evaluate renal function in humans exposed to uranium via biomarkers and hard clinical measures (such as creatinine clearance) compared to humans with low/no uranium exposure. In order to not include the same cohort multiple times in the statistical analyses, we selected studies that evaluated an outcome of interest for a given cohort for the longest follow-up period. When this was not possible (due to multiple studies using different combinations of cohorts with varying lengths of follow up), the study with the largest study population size was selected.
APA, Harvard, Vancouver, ISO, and other styles
8

ZHAO, Wen-Man, Shu-Man TAO, and Giu-Ling LIU. Neutrophil-to-lymphocyte ratio in relation to the risk of all-cause mortality and cardiovascular events among patients with chronic kidney disease: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2020. http://dx.doi.org/10.37766/inplasy2020.6.0112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wei, Dongmei, Yang Sun, and Hankang Hen. Effects of Baduanjin exercise on cardiac rehabilitation after percutaneous coronary intervention: A protocol for systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0080.

Full text
Abstract:
Review question / Objective: Can Baduanjin exercise improve the cardiac rehabilitation of patients with coronary artery disease after percutaneous coronary artery surgery? Condition being studied: Coronary heart disease (CHD), also known as coronary artery disease (CAD), is the single most common cause of death globally, with 7.4 million deaths in 2013, accounting for one-third of all deaths (WHO 2014). PCI has been shown to be effective in reducing mortality in patients with CHD. During follow-up, it has been shown that the benefits of PCI can be offset by the significant risks of coronary spasm, endothelial cell injury, recurrent ischemia, and even restenosis or thrombus. Numerous guidelines endorse the necessity for cardiac rehabilitation (CR), which is recommended for patients with chronic stable angina, acute coronary syndrome and for patients following PCI. Baduanjin have been widely practised in China for centuries, and as they are considered to be low risk interventions, their use for the prevention of cardiovascular disease is now becoming more widespread. The ability of Baduanjin to promote clinically meaningful influences in patients with CHD after PCI, however, still remains unclear.
APA, Harvard, Vancouver, ISO, and other styles
10

Zhao, Yu, WenWen Bao, BoYi Yang, JingHong Liang, ZhaoHuan Gui, Shan Huang, YiCan Chen, GuangHui Dong, and YaJun Chen. Association between Greenspace and Blood Pressure: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2021. http://dx.doi.org/10.37766/inplasy2021.10.0033.

Full text
Abstract:
Review question / Objective: Hypertension is a major risk factor for cardiovascular disease, which remains the leading cause of mortality worldwide. Urban environment as an possible cause of hypertension has received great attention. We aimed to systematically review the associations between greenspace and blood pressure (BP) levels/hypertension and use a meta-analysis to quantify the effects of greenspace on BP levels/hypertension. Condition being studied: Many epidemiological studies have assessed associations of greenspace with blood pressure levels and/or the prevalence of hypertension, whereas the results was inconsistent with some studies showing positive association but the others reporting null or negative associations. Systematic review and meta-analysis was conducted to synthesize data quantitatively across studies based on the primary outcome.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cardiovascular Disease Mortality' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography